Disease Markers / 2016 / Article / Tab 1

Research Article

Effects of Ramipril and Telmisartan on Plasma Concentrations of Low Molecular Weight and Protein Thiols and Carotid Intima Media Thickness in Patients with Chronic Kidney Disease

Table 1

Demographic and clinical characteristics of CKD randomized groups.

CKD ()Group 1 ()
Telmisartan/ramipril
40/5 mg/day
Group 2 ()
Telmisartan
80 mg/day
Mean ± SD
or median (IQR)
Mean ± SD
or median (IQR)
Mean ± SD
or median (IQR)

Sex, F/M (% F)8/16 (33%)4/8 (33%)4/8 (33%)
Age, years60 ± 1262 ± 1258 ± 13
Systolic BP, mmHg133 ± 13132 ± 13133 ± 14
Diastolic BP, mmHg80 ± 982 ± 877 ± 9
Creatinine, mg/dL1.6 (1.1–2.1)1.6 (1.0–2.3)1.7 (1.3–2.0)
GFR, mL/min per 1.73 m248 (32–66)48 (22–71)48 (34–66)
Proteinuria, g/24 h0.95 (0.30–2.35)0.52 (0.28–2.49)1.28 (0.36–2.35)
IMT, mm0.90 (0.73–1.00)0.95 (0.72–1.05)0.88 (0.73–1.00)
Total LMW thiols
 t-CysGly, µmol/L30.2 ± 8.631.6 ± 8.828.8 ± 8.4
 t-Hcy, µmol/L17.0 (12.1–24.4)16.3 (12.1–26.3)19.2 (11.8–23.7)
 t-Cys, µmol/L381 ± 98391 ± 89370 ± 109
 t-GSH, µmol/L7.5 ± 2.67.4 ± 2.17.6 ± 3.2
 t-GluCys, µmol/L5.8 (3.9–6.5)5.7 (4.5–6.0)5.4 (3.5–7.6)
 Sum of total LMW thiols, µmol/L444 ± 112458 ± 106432 ± 122
Reduced LMW thiols
 r-Cys-Gly, µmol/L6.2 ± 2.25.8 ± 1.66.6 ± 2.6
 r-Hcy, µmol/L0.24 (0.15–0.37)0.20 (0.13–0.37)0.29 (0.18–0.37)
 r-Cys, µmol/L21.6 ± 4.120.9 ± 4.721.9 ± 3.5
 r-GSH, µmol/L1.09 (0.78–1.46)1.01 (0.74–1.31)1.11 (0.85–1.67)
 r-Glu-Cys, µmol/L0.36 (0.26–0.46)0.35 (0.22–0.58)0.37 (0.27–0.44)
 Sum of reduced LMW thiols, µmol/L29.4 ± 5.928.4 ± 5.930.5 ± 6.0
Thiols redox status
 LMW redox, %0.072 ± 0.0270.066 ± 0.0230.078 ± 0.030
 PSH, µmol/g prot3.95 (3.31–4.80)3.59 (3.23–4.15)4.61 (3.39–5.80)